Hybio Pharmaceutical's H1 revenue continues to decline. Have active pharmaceutical ingredient orders become a "lifesaver"? | Interpretations
①In the first half of this year, hybio pharmaceutical's revenue decline trend has not stopped, and the net profit loss has narrowed to a certain extent; ②The formulation sector has been affected by block orders, with continuous revenue decline, and the active pharmaceutical ingredient sector has become the top revenue contributor; ③In the first half of this year, with efforts from multiple parties, hybio pharmaceutical has seen some relief in cash flow.
Is GLP-1, a concept stock, stuck in a money market quagmire due to the transfer of controlling shareholders' pledged loan shares worth 0.2 billion?
On the evening of the 15th, hybio pharmaceutical, a GLP-1 concept stock, announced that its controlling shareholder had transferred the pledged stocks worth more than 0.2 billion yuan to Shenzhen Guarantee. In the past year and the first quarter of this year, the controlling shareholder lent money to hybio pharmaceutical several times, while the financial reports for last year and Q1 of this year showed that hybio pharmaceutical's cash flow was relatively tight. The lawyer stated that the bottom line of the aforementioned stock pledge financing by the shareholder was in compliance and had no direct relation to hybio pharmaceutical's cash flow.
New developments in the case of former president's embezzlement, hybio pharmaceutical quickly made a statement! | Speed reading announcement
Hybio Pharmaceutical announced the new development of the former CEO's suspected crime case, and the company immediately stated zero tolerance for illegal behavior. Prior to this, the case has gone through a first trial and sent back for retrial. The lawyer stated that when there are situations such as unclear or erroneous factual determinations and omissions of parties, the higher court will send the case back to the original court for retrial.
"1 yuan stock" dominates the top gainers list! Multiple companies are urgently rescuing themselves, is the dawn coming?
Recently, companies such as Wintime Energy, Zhongfu Straits, Dezhan Healthcare, Guangdong Meiyan Jixiang Hydropower, and Shenzhen Heungkong Holding have all announced buyback plans.
The general manager is released on bail, while the chairman of the board is detained. Two companies have disclosed the latest situation of their executives in a bulletin | Speed-read notice.
For the purpose of investigating a safety accident, Pu Jianying, the general manager of Jiangsu Asia-Pacific Light Alloy Technology, has been released on bail pending trial. Due to being detained and unable to perform duties, Yang Yongping, the chairman and general manager of Shanghai Xuerong Bio-technology, has had their responsibilities taken over by other executives of the company.
"King Oyster Mushroom King" has been placed under detention, with the company losing money for three consecutive years according to the quick announcement.
① Yang Yongping, the Chairman of Shanghai Xuerong Bio-Technology, has been subjected to detention measures, and the company is not aware of the progress or conclusion of the detention investigation. ② Yang Yongping received a warning letter from the Shanghai regulatory bureau last year due to inaccurate financial data disclosure. ③ From 2021 to 2023, the net income of the company was in a loss position.